Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide + ADT + transarterial docetaxel infusion in metastatic hormone-sensitive prostate cancer
ChiCTR2500096519Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide and docetaxel in prostate cancer (PCa), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: PSA response. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
darolutamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500096519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096519.